BLFS vs BFLY vs AZTA vs CYRX vs RGEN

For growth investors, Butterfly Network, Inc.

(BFLY) is the stronger pick with 19. 0% revenue growth year-over-year, versus -24. 5% for Cryoport, Inc. (CYRX). Cryoport, Inc. (CYRX) offers the better valuation at 8. 7x trailing P/E, making it the more compelling value choice. Analysts rate BioLife Solutions, Inc. (BLFS) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Cryoport, Inc.

(CYRX) is the cheapest at 8. 7x versus Repligen Corporation at 146. 2x. On forward P/E, Azenta, Inc. is actually cheaper at 23. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, BioLife Solutions, Inc.

(BLFS) delivered a total return of -33. 1%, compared to -80. 2% for Cryoport, Inc. (CYRX). Over 10 years, the gap is even starker: BLFS returned +1143% versus BFLY's -54. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioLife Solutions, Inc.

(BLFS) is the lower-risk stock at 1. 67β versus Butterfly Network, Inc. 's 3. 28β — meaning BFLY is approximately 96% more volatile than BLFS relative to the S&P 500. On balance sheet safety, BioLife Solutions, Inc. (BLFS) carries a lower debt/equity ratio of 3% versus 46% for Cryoport, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Butterfly Network, Inc.

(BFLY) is pulling ahead at 19. 0% versus -24. 5% for Cryoport, Inc. (CYRX). On earnings-per-share growth, the picture is similar: Repligen Corporation grew EPS 287. 0% year-over-year, compared to 8. 8% for Butterfly Network, Inc.. Over a 3-year CAGR, BFLY leads at 10. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Cryoport, Inc.

(CYRX) is the more profitable company, earning 39. 9% net margin versus -79. 0% for Butterfly Network, Inc. — meaning it keeps 39. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RGEN leads at 8. 1% versus -88. 5% for BFLY. At the gross margin level — before operating expenses — BLFS leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Azenta, Inc.

(AZTA) trades at 23. 4x forward P/E versus 147. 2x for BioLife Solutions, Inc. — 123. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 81. 5% to $44. 67.

In this comparison, CYRX (1.

3% yield) pays a dividend. BLFS, BFLY, AZTA, RGEN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, BioLife Solutions, Inc.

(BLFS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+1143% 10Y return). Butterfly Network, Inc. (BFLY) carries a higher beta of 3. 28 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BLFS: +1143%, BFLY: -54. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BLFS (Healthcare) and BFLY (Healthcare) and AZTA (Healthcare) and CYRX (Industrials) and RGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BLFS is a small-cap high-growth stock; BFLY is a small-cap high-growth stock; AZTA is a small-cap quality compounder stock; CYRX is a small-cap deep-value stock; RGEN is a small-cap high-growth stock. CYRX pays a dividend while BLFS, BFLY, AZTA, RGEN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.